Clinical trials: Nonalcoholic Steatohepatitis
Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH)
The Sonic Incytes Liver Incytes System, Evaluation of Liver Fibrosis and Steatosis Versus MRE and MRI PDFF
The main purpose of this study is to compare the effectiveness of various non-invasive elastography techniques at determining liver stiffness measures in human subjects.
- Conditions
- Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH), Liver Fibroses, Liver Steatoses
- Trial name
- NCT04682600
- Testing
- Liver Incytes System
- Where
- United States
- Volunteers
- 164 people, healthy volunteers welcome
- Sponsor
- Sonic Incytes
Non-Alcoholic Steatohepatitis
A Proof-of-principle Study of Oral Treatment of Non-alcoholic Steatohepatitis With a Novel PDE4 Inhibitor ASP9831
The aim of this study is to explore the effect of a new drug (ASP9831) in patients with non-alcoholic steatohepatitis (NASH) by assessing clinical signs, laboratory data and biomarkers during a 12 week treatment period
- Trial name
- ASTER (NCT00668070)
- Testing
- ASP9831
- Where
- 30 sites in Belgium, Czechia and 5 more
- Volunteers
- 114 people
- Sponsor
- Astellas Pharma Inc
Type 2 Diabetes
A Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy
The purpose of this study is to identify the risk of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes in clinical practice and to evaluate the clinical usefulness of Dapagliflozin/Pioglitazone…
- Trial name
- NCT06649162
- Where
- 2 sites in South Korea
- Volunteers
- 10,000 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Non-alcoholic Fatty Liver Disease
Effect of Empagliflozin on Liver Fat in Non-diabetic Patients
Non-alcoholic fatty liver disease (NAFLD) is a global epidemic with a prevalence of 25%. Currently therapies for NAFLD patients without diabetes mellitus (DM) are limited, and are associated with various adverse side effects.
- Trial name
- NCT04642261
- Testing
- Empagliflozin 10 MG
- Where
- Hong Kong
- Volunteers
- 98 people
- Sponsor
- The University of Hong Kong
Type 2 Diabetes, NAFLD
Nutraceutical Improvement of Glucose Metabolism, NAFLD and Insulin Resistance by Oat-fiber Supplementation in Type 2 Diabetes Mellitus Patients
Cohort studies show an association between increased intake of insoluble (cereal) fiber and decreased risk for cardiovascular disease, type 2 diabetes (T2DM), non-alcoholic fatty liver disease (NAFLD), cancer, infectious and…
- Trial name
- NIMROD (NCT05654805)
- Testing
- Drinking powder supplement
- Where
- Germany
- Volunteers
- 92 people
- Sponsor
- Charite University, Berlin, Germany
Alcohol-associated Fatty Liver Disease
High-Protein Diet for Improving Alcoholic Fatty Liver Disease
Alcohol-associated liver disease (ALD) is a major cause of mortality from malignant liver diseases, accounting for 47.9% of cirrhosis-related deaths and 30% of liver cancer-related deaths annually.
- Trial name
- HP-AFLD-RCT (NCT07632222)
- Testing
- high protein diet, control diet, perilla peptide dietary group
- Volunteers
- 74 people
- Sponsor
- Li Lab,MD
Non Alcoholic Steatohepatitis, Hyperuricemia
Comparative Study Between Febuxostat Versus Vitamin E in Non-alcoholic Steatohepatitis Patients With Hyperuricemia
This study aims at evaluating and comparing the protective outcomes of using Febuxostat versus Vitamin E in Hyperuricemia non-alcoholic steatohepatitis patients without cirrhosis.
- Trial name
- NCT05574036
- Testing
- Febuxostat 80 MG Oral Tablet, vit E
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Tanta University
Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis
The Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Adults
Nonalcoholic fatty liver disease (NAFLD) is a global health concern with a suspected increasing prevalence due to the rise in obesity and diabetes mellitus.
- Trial name
- PREV (NCT03142867)
- Testing
- non-applicable
- Where
- United States
- Volunteers
- 826 people, healthy volunteers welcome
- Sponsor
- The Geneva Foundation
Type 2 Diabetes
Risk of CKD in Diabetic Patients With MAFLD
This cross-sectional study of 300 participants investigates the risk of chronic kidney disease (CKD) in individuals with metabolic dysfunction-associated fatty liver disease (MAFLD) and type 2 diabetes.
- Trial name
- NCT06304844
- Testing
- transient elastography (Fibroscan)
- Volunteers
- 300 people
- Sponsor
- Sohag University
Obesity, Nonalcoholic Fatty Liver
Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity
The goal of this study is to evaluate the role of transcription factor EB (TFEB) in adipose (fat) tissue macrophages (ATM) in regulating adipose tissue and systemic metabolic function in obesity.
- Conditions
- Obesity, Nonalcoholic Fatty Liver, Diabetes Type 2, Healthy
- Trial name
- ATM (NCT06335771)
- Testing
- Dietary consultation weight loss intervention
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Bettina Mittendorfer
NASH - Nonalcoholic Steatohepatitis
Evaluation of an Endoscopic Sutured Gastroplasty in Patients With NonAlcoholic Steatohepatitis (NASH) and Fibrosis.
Nonalcoholic fatty liver disease (NAFLD) is a spectrum of liver diseases characterized by liver steatosis which can, in a minority of patients, progress to nonalcoholic steatohepatitis (NASH), fibrosis, and ultimately…
- Trial name
- ENDONASH (NCT04653311)
- Testing
- Endomina®
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Erasme University Hospital
NAFLD
Understanding the Role of Dietary Fatty Acids on Liver Fat Metabolism in Humans
High levels of fatty substances in the blood increase the risk of developing heart disease. Investigators know a lot about one of these fatty substances, cholesterol.
- Trial name
- NCT01936779
- Testing
- Dietary supplement: fatty acid
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Oxford
HIV Infections
2000 HIV Human Functional Genomics Partnership Program
Background Chronic HIV infection leads to a dysregulated immune system, even when full viral suppression is achieved. HIV causes persistent immune activation, relating to an array of common non-AIDS-related diseases such as…
- Trial name
- 2000HIV (NCT03994835)
- Where
- 4 sites in Netherlands
- Volunteers
- 1,910 people
- Sponsor
- Radboud University Medical Center
NAFLD Cirrhosis
Dapagliflozin in Non Alcoholic Fatty Liver Disease Associated Cirrhosis and Its Role in Preventing Development of Chronic Kidney Disease.
The role of Dapagliflozin in the improvement in CKD in both diabetic and non-diabetic patients has been evaluated in the past. SGLT2i have also been found to be beneficial in NAFLD patients in improving the liver function…
- Trial name
- NCT05849220
- Testing
- Dapagliflozin, Standard of Care
- Where
- India
- Volunteers
- 144 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Non-alcoholic Steatohepatitis (NASH)
FTIH of ECC4703 in Healthy Volunteers
This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study of ECC4703 in healthy volunteers and participants with treatment unnecessary LDL-C under 160 mg/dL
- Trial name
- NCT05552274
- Testing
- ECC4703
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Eccogene
Non Alcoholic Fatty Liver Disease
Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes
Fatty liver disease is an increasingly recognized health problem in patients with type 2 diabetes mellitus (T2DM). Sodium glucose co-transporter type 2 (SGLT-2) inhibitors are a new class of anti-diabetic agents that cause weight…
- Trial name
- E-LIFT (NCT02686476)
- Testing
- Empagliflozin
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Medanta, The Medicity, India
Non-Alcoholic Fatty Liver Disease
Effect of Alpha Lipoic Acid on Non-alcoholic Fatty Liver Diseases
In developed counties Non-alcoholic fatty liver disease (NAFLD) becomes the most common cause of chronic liver disease , but its prevalence in developing countries like India is also increasing (10 -20%).Till date, there is no…
- Trial name
- NCT04475276
- Testing
- Alphalipoic acid
- Where
- India
- Volunteers
- 120 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Liver Disease
The Effect of Probiotics on Non Alcoholic Fatty Liver Disease
Nonalcoholic Fatty Liver Disease (NAFLD) has been suggested to be the most common cause of chronic liver disease in the general population in the Western World.
- Trial name
- NCT00808990
- Testing
- BioFemale
- Where
- Israel
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Rabin Medical Center
Metabolic Parameters and Liver Histology
Pentoxifylline Versus Pioglitazone In Non-Alcoholic Steatohepatiti (NASH)
1. To assess the metabolic factors in lean and obese patients with NASH. 2. To compare the efficacy of pentoxifylline versus pioglitazone on the metabolic profile and liver histology of NASH patients.
- Trial name
- NASH (NCT00681733)
- Testing
- Pioglitazone, Pentoxifylline
- Where
- India
- Volunteers
- 20 people
- Sponsor
- Govind Ballabh Pant Hospital
Non-alcoholic Fatty Liver Disease
Validity of Laboratory Biomarkers in Diagnosis of Nonalcoholic Fatty Liver Disease (NAFLD) and It's Consequences
The validity of laboratory biomarkers in the diagnosis of NAFLD is still not established, and adherence to a healthy dietary lifestyle for those patients in our community is not well studied.
- Trial name
- NCT06908122
- Testing
- laboratory biomarkers in the diagnosis of NAFLD disease
- Volunteers
- 100 people
- Sponsor
- Assiut University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.